** Shares of medical diagnostics co Lantheus Holdings LNTH.O fall 7.4% to $91.03
** LNTH says it will buy Evergreen Theragnostics to expand its oncology radiopharmaceutical pipeline with multiple experimental cancer treatments
** Deal consists of an upfront payment of $250 mln and up to $752.5 mln in milestone payments to Evergreen
** JonesTrading analyst Justin Walsh says current weakness in LNTH is due to concerns about the co deploying cash on acquisitions that are expected to add to EPS only ~18 months post-close; he believes this market reaction is "wholly unwarranted"
** Deal expected to close in H2 2025
** 12 of 13 brokerages rate the stock "buy" or higher and 1 "hold"; their median PT is $135 - LSEG
** LNTH gained 41.8% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。